27 citations
,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
25 citations
,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
24 citations
,
April 2014 in “Oncotarget” Minoxidil can reduce functions related to androgen receptors.
1 citations
,
July 2017 in “Global journal of pharmacy & pharmaceutical sciences” A new hair loss treatment was created using minoxidil and tretinoin in stable niosomes, which effectively released the drugs over time.
September 2025 in “Journal of the American Academy of Dermatology” Reducing SFRP1 can promote hair growth and may help treat hair loss.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
72 citations
,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
65 citations
,
February 2009 in “The journal of investigative dermatology/Journal of investigative dermatology” Anti-acne medications may work by reducing the activity of a protein involved in acne development.
1 citations
,
January 1981 in “Elsevier eBooks” Melatonin stops melanin production after tyrosinase action, with cyclic GMP mimicking this effect.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
1 citations
,
April 2013 in “PubMed” November 2025 in “Journal of Investigative Dermatology”
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
December 2024 in “International Journal of Molecular Sciences” Platelet-rich fibrin may help reduce nonmelanoma skin cancer cell growth.
51 citations
,
June 1970 in “British journal of dermatology/British journal of dermatology, Supplement” Antiandrogens may help treat conditions like excessive hair growth, prostate tumors, male baldness, and acne by blocking male hormone effects.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
15 citations
,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.